Lara Aprile
A5055619912- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Eosinophilic Disorders and Syndromes
- Peptidase Inhibition and Analysis
- Platelet Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Complement system in diseases
- HER2/EGFR in Cancer Research
- Mast cells and histamine
- RNA Interference and Gene Delivery
- CAR-T cell therapy research
- HIV/AIDS drug development and treatment
- Immunotherapy and Immune Responses
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- PI3K/AKT/mTOR signaling in cancer
- Neutropenia and Cancer Infections
- vaccines and immunoinformatics approaches
- Quinazolinone synthesis and applications
- Kruppel-like factors research
- Lymphoma Diagnosis and Treatment
- Silkworms and Sericulture Research
Azienda Ospedaliera S.Giuseppe Moscati
2019-2024
Azienda Ospedaliera Universitaria Senese
2016-2024
Presidio Ospedaliero
2023
University of Siena
2009-2020
Hudson Institute
2020
John Wiley & Sons (United States)
2020
National Medical Research Center for Hematology
2019
Ospedale Santa Maria alle Scotte
2016-2017
Chronic Myeloid Leukemia (CML) patients in sustained "deep molecular response" (DMR) may stop TKI treatment without disease recurrence; however, half of them lose response shortly after withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still missing. Relapse is probably due residual quiescent resistant leukemic stem cells (LSCs) supposedly transcriptionally low/silent and not easily detectable by BCR-ABL1 qRT-PCR. Bone marrow Ph+CML CD34+/CD38-LSCs...
The outcome of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL) in adults is poor, with less than 20% patients surviving at 5 years. Nelarabine the only drug specifically approved for R/R T-ALL/T-LBL, but information to support its use based on limited available data. aim this observational phase four study was provide recent additional data efficacy and safety nelarabine T-ALL/T-LBL evaluate feasibility allogeneic hematopoietic stem cell transplant...
// Monica Bocchia 1 , Sara Galimberti 2 Lara Aprile Anna Sicuranza Antonella Gozzini 3 Francesca Santilli 4 Elisabetta Abruzzese 5 Claudia Baratè Barbara Scappini Giulia Fontanelli Monika Malgorzata Trawinska Marzia Defina Alessandro Gozzetti Alberto Bosi Mario Petrini and Luca Puccetti Department of Hematology, University Siena, Azienda Ospedaliera Universitaria Senese, Italy Clinical Experimental Medicine, U.O. Pisa, Functional Unit Florence, Medicine Aging, Chieti, Hematology Unit,...
Abstract Background Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are eligible discontinuation. For these patients, only alternative to assume TKI continuously, lifelong. Methods The Italian phase III multicentric randomized OPTkIMA study started in 2015, aim evaluate if progressive de‐escalation (imatinib, nilotinib, dasatinib) able maintain (MR 3.0 ) improve Health Related Quality Life...
Abstract BACKGROUND: Compared with imatinib, nilotinib is a potent breakpoint cluster region/v‐abl Abelson murine leukemia viral oncogene (bcr‐abl) kinase inhibitor, and it induces higher rate rapid complete cytogenetic response (CCyR), yet no clinical data are available regarding its efficacy against chronic myeloid (CML) stem cells. Earlier studies demonstrated that clusters of differentiation 34–positive, Philadelphia chromosome–positive (CD34 + Ph ) cells detectable in about 45% patients...
First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed one-third of patients. The toxicity efficacy tyrosine kinase inhibitors might depend on the activity transmembrane transporters. However, impact transporters genes polymorphisms setting still debated. We investigated possible correlation between single nucleotide hOCT1 (rs683369 [c.480C>G]) ABCB1 (rs1128503 [c.1236C>T],...
The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL) has significantly improved patients' prognosis. Within the Campus ALL network we analyzed outcome Ph-ALL patients treated according to GIMEMA LAL1913 protocol outside clinical trial, compare real-life data with study results. We included 421 consecutive patients, a median age 42 years. complete remission (CR) rate after first course chemotherapy was 94% and measurable residual...
Decitabine, a DNA hypomethylating agent, was approved for use in adults with acute myeloid leukemia (AML) not eligible standard chemotherapy and is now widely accepted as treatment. Although number of clinical trials demonstrated its benefits elderly AML patients, older patients frequent comorbidities are typically under-represented such settings. Thus, the aim present study to evaluate, real-world setting, effectiveness toxicity decitabine administered single agent unselected previously...
Background: Family planning is important in patients (pts) with chronic myeloid leukemia (CML) who can have a near normal lifespan tyrosine kinase inhibitors (TKI) era. Management of CML on conceptions and pregnancies not defined as cases are rare data scarce. To investigate this issue multicenter retrospective prospective observational study conception/pregnancy pts was initiated within the European LeukemiaNet (ELN) from February 2014 till present. All ELN centers participants other...
Role of erythropoietin (EPO) in the treatment late anemia patients with Chronic Myeloid Leukemia (CML) is still undefined.Fifty CML treated at 14 institutions frontline imatinib for least 12 months and stable complete cytogenetic response who developed a chronic EPO were retrospectively evaluated.Median time from start to was 42.2 [interquartile range (IQR) 20.8-91.9]. Median Hb value starting 9.9 g/dL (IQR 8.9-10.3): Eleven (22.0%) transfusion dependent. Alpha-EPO (40 000 UI weekly)...
Endothelium damage triggers the multimeric protein von Willebrand factor (VWF) release and subsequent binding to platelets, which are recruited at sites of vascular injury. A complex fragile equilibrium between circulating levels its metalloprotease, ADAMTS13, is responsible for hemostatic balance. However, presence autoantibodies targeting ADAMTS13 results in an increase factor, mainly ultra-large multimers. The latter lead platelet aggregation, formation thrombi microangiopathic hemolytic...